{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:32:03Z","timestamp":1772634723016,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005849","name":"Baqiyatallah University of Medical Sciences","doi-asserted-by":"publisher","award":["5121"],"award-info":[{"award-number":["5121"]}],"id":[{"id":"10.13039\/501100005849","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.molimm.2022.06.007","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:58:32Z","timestamp":1655945912000},"page":"107-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models"],"prefix":"10.1016","volume":"149","author":[{"given":"Shahram","family":"Nazarian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholamreza","family":"Olad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raziyeh","family":"Abdolhamidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Javad","family":"Motamedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rouhollah","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emad","family":"Kordbacheh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Felagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanieh","family":"Olad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Bahiraee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parisa","family":"Farahani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Haghighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faezeh","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahideh","family":"Hajhassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Nadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdolkarim","family":"Sheikhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jafar","family":"Salimian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jafar","family":"Amani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2022.06.007_bib1","article-title":"Safety and potency of COVIran barekat inactivated vaccine candidate for SARS-CoV-2: a preclinical study","author":"Abdoli","year":"2021","journal-title":"bioRxiv"},{"issue":"7862","key":"10.1016\/j.molimm.2022.06.007_bib2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41586-021-03530-2","article-title":"Adjuvanting a subunit COVID-19 vaccine to induce protective immunity","volume":"594","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.molimm.2022.06.007_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.immunol.15.1.235","article-title":"Neutralizing antiviral B cell responses","volume":"15","author":"Bachmann","year":"1997","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.molimm.2022.06.007_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.pep.2006.03.007","article-title":"Cloning, purification, and characterization of a non-collagenous anti-angiogenic protein domain from human \u03b11 type IV collagen expressed in Sf9 cells","volume":"49","author":"Boosani","year":"2006","journal-title":"Protein Expr. Purif."},{"issue":"6504","key":"10.1016\/j.molimm.2022.06.007_bib5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.molimm.2022.06.007_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1128\/JVI.01925-19","article-title":"Nucleocapsid protein recruitment to replication-transcription complexes plays a crucial role in coronaviral life cycle","volume":"94","author":"Cong","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.molimm.2022.06.007_bib7","unstructured":"Coronavirus, N., 2019. Situation Report, 22. World Health Organization. \u3008https:\/\/wwwwhoint\/docs\/default-source\/coronaviruse\/situation-reports\/20200211-sitrep-22-ncovpdf\u3009."},{"issue":"2","key":"10.1016\/j.molimm.2022.06.007_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.molimm.2022.06.007_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030525","article-title":"Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants","volume":"3","author":"Deming","year":"2006","journal-title":"PLoS Med."},{"issue":"2","key":"10.1016\/j.molimm.2022.06.007_bib10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4103\/ijmr.IJMR_761_20","article-title":"Responding to COVID-19 pandemic: Why a strong health system is required","volume":"151","author":"Dikid","year":"2020","journal-title":"Indian J. Med. Res."},{"issue":"1","key":"10.1016\/j.molimm.2022.06.007_bib11","first-page":"1","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"15","key":"10.1016\/j.molimm.2022.06.007_bib12","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/j.vaccine.2006.10.031","article-title":"Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model","volume":"25","author":"Du","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.molimm.2022.06.007_bib13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virol.2009.07.018","article-title":"Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity","volume":"393","author":"Du","year":"2009","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.molimm.2022.06.007_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000151532","article-title":"Expression and purification of a recombinant adenovirus fiber knob in a baculovirus system","volume":"51","author":"Farinha-Arcieri","year":"2008","journal-title":"Intervirology"},{"issue":"10249","key":"10.1016\/j.molimm.2022.06.007_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"9399","key":"10.1016\/j.molimm.2022.06.007_bib16","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(03)14962-8","article-title":"Effects of a SARS-associated coronavirus vaccine in monkeys","volume":"362","author":"Gao","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.molimm.2022.06.007_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.7774\/cevr.2021.10.1.24","article-title":"Biological properties the novel application of N-trimethyl chitosan nanospheres as a stabilizer and preservative in tetanus vaccine","volume":"10","author":"Ghalavand","year":"2021","journal-title":"Clin. Exp. Vaccin. Res."},{"issue":"7","key":"10.1016\/j.molimm.2022.06.007_bib18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.molimm.2022.06.007_bib19","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.molimm.2022.06.007_bib20","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2022.06.007_bib21","article-title":"Oxford-AstraZeneca COVID-19 vaccine efficacy","author":"Knoll","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.molimm.2022.06.007_bib22","series-title":"A Race to Determine What Drives COVID-19 Severity","author":"Koutsakos","year":"2020"},{"issue":"2","key":"10.1016\/j.molimm.2022.06.007_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/422040","article-title":"Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid","volume":"190","author":"Leung","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"16","key":"10.1016\/j.molimm.2022.06.007_bib24","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1016\/j.vaccine.2006.01.058","article-title":"Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates","volume":"24","author":"Liu","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2022.06.007_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2016.11.006","article-title":"T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV","volume":"137","author":"Liu","year":"2017","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.molimm.2022.06.007_bib26","first-page":"1","article-title":"RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response","volume":"5","author":"Liu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10256","key":"10.1016\/j.molimm.2022.06.007_bib27","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S0140-6736(20)31970-X","article-title":"Safety and efficacy of the Russian COVID-19 vaccine: more information needed - authors\u2019 reply","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"issue":"10255","key":"10.1016\/j.molimm.2022.06.007_bib28","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.molimm.2022.06.007_bib29","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.molimm.2022.06.007_bib30","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3389\/fimmu.2017.01175","article-title":"Adjuvant-mediated epitope specificity and enhanced neutralizing activity of antibodies targeting dengue virus envelope protein","volume":"8","author":"Maeda","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2022.06.007_bib31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1110\/ps.051812706","article-title":"Comparison of SUMO fusion technology with traditional gene fusion systems: enhanced expression and solubility with SUMO","volume":"15","author":"Marblestone","year":"2006","journal-title":"Protein Sci."},{"issue":"7830","key":"10.1016\/j.molimm.2022.06.007_bib32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"17\u201318","key":"10.1016\/j.molimm.2022.06.007_bib33","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.vaccine.2005.01.036","article-title":"The development of vaccines against SARS corona virus in mice and SCID-PBL\/hu mice","volume":"23","author":"Okada","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2022.06.007_bib34","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2022.06.007_bib35","article-title":"Bacterial expression and purification of functional recombinant SARS-CoV-2 spike receptor binding domain","author":"Prahlad","year":"2021","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.molimm.2022.06.007_bib36","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.molimm.2022.06.007_bib37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.micpath.2018.12.003","article-title":"Different frequencies of memory B-cells induced by tetanus, botulinum, and heat-labile toxin binding domains","volume":"127","author":"Rezaie","year":"2019","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.molimm.2022.06.007_bib38","article-title":"BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans","author":"Sahin","year":"2020","journal-title":"medRxiv"},{"issue":"7830","key":"10.1016\/j.molimm.2022.06.007_bib39","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.molimm.2022.06.007_bib40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-59745-566-4_14","article-title":"Strategies for the expression of SUMO-modified target proteins in Escherichia coli","author":"Saitoh","year":"2009","journal-title":"SUMO Protoc."},{"key":"10.1016\/j.molimm.2022.06.007_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118056","article-title":"Structural features of coronavirus SARS-CoV-2 spike protein: targets for vaccination","author":"Sternberg","year":"2020","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.molimm.2022.06.007_bib42","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","article-title":"Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment","volume":"182","author":"Sun","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.molimm.2022.06.007_bib43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41591-020-0819-2","article-title":"Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19","volume":"26","author":"Thevarajan","year":"2020","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.molimm.2022.06.007_bib44","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice","volume":"12","author":"Tian","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molimm.2022.06.007_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.11.032","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.molimm.2022.06.007_bib46","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.molimm.2022.06.007_bib47","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/toxins8090266","article-title":"Tetanus neurotoxin neutralizing antibodies screened from a human immune scFv antibody phage display library","volume":"8","author":"Wang","year":"2016","journal-title":"Toxins"},{"issue":"6","key":"10.1016\/j.molimm.2022.06.007_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-020-01744-7","article-title":"The COVID-19 vaccine race: challenges and opportunities in vaccine formulation","volume":"21","author":"Wang","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.molimm.2022.06.007_bib49","article-title":"Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China","author":"Wang","year":"2020","journal-title":"medRxiv"},{"issue":"2","key":"10.1016\/j.molimm.2022.06.007_bib50","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jmv.26320","article-title":"SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen","volume":"93","author":"Wang","year":"2021","journal-title":"J. Med. Virol."},{"issue":"7830","key":"10.1016\/j.molimm.2022.06.007_bib51","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.molimm.2022.06.007_bib52","first-page":"593","article-title":"Strategies for vaccine development of COVID-19. Sheng wu gong cheng xue bao=","volume":"36","author":"Yang","year":"2020","journal-title":"Chin. J. Biotechnol."},{"key":"10.1016\/j.molimm.2022.06.007_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","author":"Yang","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"8","key":"10.1016\/j.molimm.2022.06.007_bib54","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"9","key":"10.1016\/j.molimm.2022.06.007_bib55","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J. Immunol."},{"issue":"6505","key":"10.1016\/j.molimm.2022.06.007_bib56","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.molimm.2022.06.007_bib57","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.molimm.2022.06.007_bib58","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","article-title":"Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses","volume":"44","author":"Zhao","year":"2016","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.molimm.2022.06.007_bib59","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.4049\/jimmunol.177.4.2138","article-title":"Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes","volume":"177","author":"Zhou","year":"2006","journal-title":"J. Immunol."},{"issue":"10249","key":"10.1016\/j.molimm.2022.06.007_bib60","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"10240","key":"10.1016\/j.molimm.2022.06.007_bib61","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589022003716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589022003716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:44:01Z","timestamp":1758980641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589022003716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":61,"alternative-id":["S0161589022003716"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2022.06.007","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2022.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}